NIBEC Past Earnings Performance
Past criteria checks 0/6
NIBEC's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 23.3% per year.
Key information
-15.9%
Earnings growth rate
-7.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 23.3% |
| Return on equity | -19.2% |
| Net Margin | -33.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?
Jun 18
NIBEC Co., Ltd.'s (KOSDAQ:138610) Share Price Not Quite Adding Up
Mar 28NIBEC (KOSDAQ:138610) Has Debt But No Earnings; Should You Worry?
Apr 05NIBEC (KOSDAQ:138610) Has Rewarded Shareholders With An Exceptional 411% Total Return On Their Investment
Jan 04Revenue & Expenses Breakdown
How NIBEC makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 17,578 | -5,890 | 6,761 | 3,243 |
| 31 Dec 23 | 15,704 | -6,284 | 6,110 | 3,243 |
| 30 Sep 23 | 16,213 | -10,072 | 6,230 | 5,361 |
| 30 Jun 23 | 17,493 | -6,561 | 5,258 | 5,361 |
| 31 Mar 23 | 18,878 | -5,163 | 7,157 | 4,402 |
| 31 Dec 22 | 21,670 | -3,766 | 5,884 | 5,361 |
| 30 Sep 22 | 20,077 | -678 | 9,192 | 806 |
| 30 Jun 22 | 20,776 | -846 | 8,052 | 1,492 |
| 31 Mar 22 | 18,766 | -3,340 | 5,222 | 3,735 |
| 31 Dec 21 | 13,625 | -5,740 | 4,612 | 3,333 |
| 30 Sep 21 | 12,682 | -4,419 | 3,903 | 3,356 |
| 30 Jun 21 | 9,383 | -5,519 | 3,320 | 2,937 |
| 31 Mar 21 | 7,225 | -4,834 | 2,596 | 1,957 |
| 31 Dec 20 | 6,357 | -3,638 | 2,411 | 1,535 |
| 30 Sep 20 | 6,775 | -2,314 | 2,087 | 1,354 |
| 30 Jun 20 | 7,971 | -1,830 | 2,482 | 1,358 |
| 31 Mar 20 | 8,949 | -2,235 | 2,667 | 1,646 |
| 31 Dec 19 | 9,287 | -2,727 | 2,682 | 1,683 |
| 30 Sep 19 | 7,803 | -3,589 | 2,951 | 1,640 |
| 30 Jun 19 | 6,664 | -4,022 | 2,588 | 1,453 |
| 31 Mar 19 | 5,717 | -4,021 | 2,550 | 1,347 |
| 31 Dec 18 | 5,208 | -4,146 | 2,395 | 1,204 |
| 30 Sep 18 | 5,085 | -4,556 | 2,373 | 1,134 |
| 30 Jun 18 | 5,326 | -4,127 | 2,237 | 1,065 |
| 31 Mar 18 | 5,223 | -3,406 | 2,018 | 644 |
| 31 Dec 17 | 6,303 | -2,568 | 2,210 | 641 |
| 30 Sep 17 | 6,219 | -1,683 | 2,399 | 228 |
| 30 Jun 17 | 5,890 | -2,383 | 2,724 | 292 |
| 31 Mar 17 | 5,849 | -2,280 | 2,834 | 256 |
| 31 Dec 16 | 4,804 | -3,027 | 2,848 | 252 |
| 30 Sep 16 | 4,589 | -2,823 | 2,532 | 169 |
| 30 Jun 16 | 4,600 | -2,354 | 2,413 | 108 |
| 31 Mar 16 | 4,645 | -2,586 | 2,418 | 120 |
| 31 Dec 15 | 4,174 | -2,426 | 2,248 | 114 |
| 30 Sep 15 | 3,915 | -2,317 | 2,238 | 90 |
| 30 Jun 15 | 4,010 | -2,553 | 2,420 | 59 |
| 31 Mar 15 | 4,073 | -2,957 | 2,900 | 109 |
| 31 Dec 14 | 4,786 | -3,621 | 3,650 | 149 |
| 30 Sep 14 | 4,886 | -4,663 | 3,742 | 176 |
| 30 Jun 14 | 4,386 | -4,608 | 3,541 | 194 |
| 31 Mar 14 | 3,372 | -4,328 | 2,983 | 113 |
| 31 Dec 13 | 2,272 | -3,850 | 2,153 | 88 |
| 30 Sep 13 | 2,265 | -2,553 | 1,838 | 81 |
Quality Earnings: A138610 is currently unprofitable.
Growing Profit Margin: A138610 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A138610 is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare A138610's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A138610 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A138610 has a negative Return on Equity (-19.25%), as it is currently unprofitable.